Your browser doesn't support javascript.
loading
Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract.
Wirth, G J; Haitel, A; Moschini, M; Soria, F; Klatte, T; Hassler, M R; Bensalah, K; Briganti, A; Karam, J A; Lotan, Y; Margulis, V; Raman, J D; Remzi, M; Rioux-Leclercq, N; Robinson, B D; Rouprêt, M; Wood, C G; Shariat, S F.
Afiliação
  • Wirth GJ; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medizinische Universität Wien/Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Haitel A; Division of Urology, Department of Surgery, Geneva University Hospital, Geneva, Switzerland.
  • Moschini M; Department of Clinical Pathology, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.
  • Soria F; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medizinische Universität Wien/Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Klatte T; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy.
  • Hassler MR; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medizinische Universität Wien/Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Bensalah K; Division of Urology, Department of Surgical Sciences, University of Studies of Torino, Turin, Italy.
  • Briganti A; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medizinische Universität Wien/Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Karam JA; Karl-Landsteiner Institute for Urology and Andrology, Vienna, Austria.
  • Lotan Y; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medizinische Universität Wien/Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Margulis V; Department of Urology, Centre Hospitalier Universitaire de Rennes, Rennes, France.
  • Raman JD; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy.
  • Remzi M; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rioux-Leclercq N; Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Robinson BD; Department of Urology, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
  • Rouprêt M; Division of Urology, Penn State Milton S. Hershey Medical Center, Hershey, PA, USA.
  • Wood CG; Department of Urology, Comprehensive Cancer Center, Vienna General Hospital, Medizinische Universität Wien/Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
  • Shariat SF; Department of Pathology, Centre Hospitalier Universitaire de Rennes, Rennes, France.
World J Urol ; 35(6): 943-949, 2017 Jun.
Article em En | MEDLINE | ID: mdl-27730305
ABSTRACT

PURPOSE:

This study aims to determine the significance of androgen receptor (AR) expression in urothelial carcinoma of the upper urinary tract (UTUC).

METHODS:

AR expression was assessed on tissue microarrays containing specimens of 737 patients with UTUC who underwent radical nephroureterectomy with curative intent. AR expression was correlated with clinical and pathological tumor features as well as recurrence-free survival (RFS), cancer-specific survival (CSS) and overall survival (OS).

RESULTS:

Overall, AR was expressed in 11 % of tumors. AR expression was significantly associated with tumor necrosis as well as sessile and multifocal tumor growth but not with RFS, CSS or OS. AR was detected nearly twice as often in tumors of the ureter than of the pelvicalyceal system (p = 0.005). Subgroup analyses showed that the significant associations of AR with unfavorable pathologic features were exclusively attributable to tumors located in the ureter. However, in both ureteral and pelvicalyceal tumors, AR status was independent of RFS, CSS and OS.

CONCLUSIONS:

In this cohort of patients treated with RNU, AR expression was found in approximately 10 % of UTUCs, twice as often in ureteral than in pelvicalyceal tumors. While AR expression had no impact on postoperative prognosis, it was significantly associated with unfavorable pathologic features in ureteral tumors. Steroid hormone signaling might be relevant for future investigations of differences between ureteral and pelvicalyceal tumors.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ureterais / Carcinoma de Células de Transição / Receptores Androgênicos / Regulação Neoplásica da Expressão Gênica / Neoplasias Renais Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: World J Urol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Áustria

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ureterais / Carcinoma de Células de Transição / Receptores Androgênicos / Regulação Neoplásica da Expressão Gênica / Neoplasias Renais Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: World J Urol Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Áustria